Is Wegovy HSA-eligible?▼
Yes. When prescribed for any of its FDA-approved indications (chronic weight management at BMI 30+ or BMI 27+ with comorbidity, cardiovascular risk reduction in adults with established CV disease plus overweight/obesity, or pediatric obesity in patients 12+), Wegovy is HSA-eligible under two IRS rules: the prescription-medicines rule in IRC 213(d) and the weight-loss-program rule in IRS Publication 502. Keep the prescription, pharmacy receipt, and clinician chart note documenting the qualifying diagnosis.
What is the difference between Wegovy and Ozempic?▼
Same active ingredient (semaglutide), different FDA-approved indications, different labels, different dosing. Ozempic is FDA-approved for Type 2 diabetes glycemic control and is dosed at lower strengths (0.25 to 2.0 mg weekly). Wegovy is FDA-approved for chronic weight management, cardiovascular risk reduction, and pediatric obesity, and is dosed at higher strengths (up to 2.4 mg weekly). HSA eligibility follows the prescription indication. Ozempic for diagnosed T2D qualifies under the prescription-medicines rule. Wegovy for any of its three FDA indications qualifies under both the prescription-medicines rule and the weight-loss-program rule.
Is NovoCare $499/mo HSA-eligible?▼
Yes. NovoCare Pharmacy is Novo Nordisk's self-pay program that began in March 2025, offering Wegovy vials at around $499/month for patients paying cash. The medication is still FDA-approved Wegovy dispensed under a valid prescription, which keeps it inside the IRS prescription-medicines rule in IRC 213(d). Pay with an HSA debit card if your custodian permits, or pay out-of-pocket and reimburse yourself using the NovoCare receipt plus your prescription and chart note.
Wegovy plus FEHB plans plus HSA - how does it work?▼
Federal Employees Health Benefits (FEHB) plan coverage for Wegovy varies plan by plan and year by year. Some FEHB plans cover Wegovy at Tier 3 with prior authorization; others exclude weight-management drugs entirely. Check the OPM.gov plan comparison tool and your specific plan's formulary before open season. Whatever portion you pay out-of-pocket (copay, coinsurance, or full cash price) is HSA-eligible when the prescription is for an FDA-approved indication. The HSA rule is identical for federal and private-sector employees - the only variable is what your plan covers.
Pediatric Wegovy - can a parent's HSA pay?▼
Yes if the child is a tax dependent. Wegovy was FDA-approved in December 2022 for adolescents 12 and older with obesity (BMI at or above the 95th percentile for age and sex). When the parent claims the child as a tax dependent and the child has an obesity diagnosis on the chart, the parent's HSA covers Wegovy prescriptions, visit fees, and related labs under IRC 213(d). Keep the pediatric chart note documenting the BMI percentile alongside the prescription and pharmacy receipt.
What if I switch from Wegovy to compounded semaglutide?▼
Different products with different regulatory standing. Compounded semaglutide from 503A pharmacies is still legally available for individual prescriptions because semaglutide remained on the FDA shortage list until February 2025 and 503A pharmacies retain compounding authority for patient-specific prescriptions under section 503A of the FDC Act. 503B outsourcing facilities can no longer mass-produce compounded semaglutide. The HSA eligibility analysis for compounded semaglutide is different from brand-name Wegovy. See the separate compounded semaglutide guide for that path.
When does Wegovy require a Letter of Medical Necessity?▼
Generally not when Wegovy is prescribed for any of its three FDA-approved indications. The FDA label combined with a clinician chart note showing the qualifying diagnosis (ICD-10 E66.x for obesity, I25.x for CV disease, or pediatric Z68.5x BMI percentile codes) satisfies the medical-necessity standard under IRC 213(d). An LMN is required when Wegovy is prescribed off-label for maintenance after weight loss without an ongoing obesity or CV diagnosis - that use case shifts toward cosmetic and fails the IRS Pub 502 specific-disease test without supporting documentation.
Can I use my HSA for Wegovy when I have insurance?▼
Yes for the portion you pay out-of-pocket. If insurance covers Wegovy at Tier 3, you typically pay a copay of $25 to $75 per month while the plan absorbs the balance. The copay is HSA-eligible because it is the out-of-pocket portion of a prescription medication for a diagnosed disease. Keep the Explanation of Benefits alongside the pharmacy receipt so the audit trail shows the split. Do not double-dip: the insurance-covered portion cannot also be reimbursed from your HSA under IRC 223(f)(4)(A).
What documentation do I keep for Wegovy?▼
Four documents. The prescription showing Wegovy and the indication, the pharmacy or NovoCare receipt showing date and amount paid, the clinician chart note documenting the qualifying diagnosis with ICD-10 code (E66.x for obesity, I25.x for CV disease, or pediatric BMI percentile), and the Explanation of Benefits if insurance paid any portion. For pediatric Wegovy, also keep proof of dependency status. Save digital scans in your HSA receipt file. The IRS does not specify retention length for HSA records, but seven years is the conservative standard.
Can I reimburse myself years later for past Wegovy expenses?▼
Yes, with two conditions. First, the expense must have been incurred after the HSA was opened (IRC 223(d)(2) prohibits reimbursing expenses that predate account establishment). Second, you must preserve the documentation chain - prescription, receipt, chart note - in case of audit. There is no statutory deadline for when reimbursement must occur, so a 2026 Wegovy expense can be reimbursed from your HSA in 2030 or 2040 if the receipts survive. This is the shoebox strategy applied to a long-running drug regimen.
